Top

CardioVascular and Interventional Radiology

Published in:

01-08-2014 | Clinical Investigation

Splenomegaly-Associated Thrombocytopenia After Hepatic Yttrium-90 Radioembolization

Authors: Marnix G. E. H. Lam, Arjun Banerjee, John D. Louie, Daniel Y. Sze

Published in: CardioVascular and Interventional Radiology | Issue 4/2014

Abstract

Purpose

Thrombocytopenia is often observed after yttrium-90 radioembolization (RE). Possible mechanisms include radiation toxicity to the bone marrow, consumption in the liver due to local radiation effects, and sequestration in the spleen. We sought to identify the causative factors.

Materials and Methods

Patients with complete baseline and 3-month post-RE imaging and laboratory data were included in this retrospective analysis. Univariate and multivariate regression analyses were performed on clinical, procedural, and imaging data.

Results

A total of 116 patients were identified (65 male, 51 female; median age 64 years). Forty-six patients were treated for primary and 70 for metastatic liver malignancy. Of these, 86 were treated with resin and 30 with glass microspheres; median activity was 1.85 GBq. Eighty-three patients underwent whole-liver treatment. Maximum individual change in platelet count was −20.2 % leading to new or increased grade of thrombocytopenia in 48 patients (41.4 %) by National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.02 criteria. Independent risk factors for decreased platelet count included change in spleen volume (median change +17.5 %; p = 0.001) and whole-liver (rather than lobar or segmental) treatment (p = 0.025). Administered activity and absorbed dose were not associated with change in platelet count. The change in spleen volume itself was associated with previous epidermal growth factor receptor–inhibitor treatment (p = 0.002), whole-liver absorbed dose (p = 0.027), and multiple-line chemotherapy (0.012) for whole-liver treatments only.

Conclusion

Post-RE treatment increase of spleen volume is correlated with decreased peripheral platelet count suggesting a mechanism of increased portal hypertension and hypersplenism being responsible.

Riaz A, Lewandowski RJ, Kulik LM et al (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20:1121–1130PubMedCrossRef

Carr BI (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10:S107–S110PubMedCrossRef

Salem R, Lewandowski RJ, Atassi B et al (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639PubMedCrossRef

Novell JR, Hilson A, Hobbs KE (1991) Therapeutic aspects of radio-isotopes in hepatobiliary malignancy. Br J Surg 78:901–906PubMedCrossRef

Lawrence TS, Robertson JM, Anscher MS et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248PubMedCrossRef

Jakobs TF, Saleem S, Atassi B et al (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 53:2556–2563PubMedCrossRef

Nosher JL, Ohman-Strickland PA et al (2011) Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. J Vasc Interv Radiol 22:1706–1713PubMedCrossRef

Paprottka PM, Schmidt GP, Trumm CG et al (2011) Changes in normal liver and spleen volume after radioembolization with (90)Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. Cardiovasc Intervent Radiol 34:964–972PubMedCrossRef

Nijsen JF, van het Schip AD, Hennink WE et al (2002) Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours. Curr Med Chem 9:73–82PubMedCrossRef

10.

Coldwell D, Sangro B, Wasan H et al (2011) General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 34:337–341PubMedCrossRef

11.

Dezarn WA, Cessna JT, de Werd LA et al (2011) Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 38:4824–4845PubMedCrossRef

12.

Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23PubMedCrossRef

13.

Gulec SA, Mesoloras G, Stabin M (2006) Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med 47:1209–1211PubMed

14.

Yang CW, Yen HH, Su WW et al (2010) Profound transient thrombocytopenia associated with 90-yttrium microsphere therapy for inoperable hepatoma. South Med J 103:1264–1268PubMedCrossRef

15.

Lambert B, Sturm E, Mertens J et al (2011) Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 38:2117–2124PubMedCrossRef

16.

Laznicek M, Laznickova A, Macke HR et al (2002) Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats. Cancer Biother Radiopharm 17:527–533PubMedCrossRef

17.

Hirano S, Kodama N, Shibata K et al (1993) Metabolism and toxicity of intravenously injected yttrium chloride in rats. Toxicol Appl Pharmacol 121:224–232PubMedCrossRef

18.

Kutzner J, Becker M, Grimm W (1983) Bone-seeking behavior of rhenium and yttrium complexes. Nuklearmedizin 22:162–165PubMed

19.

Baechler S, Hobbs RF, Jacene HA et al (2010) Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med 51:1878–1884PubMedCentralPubMedCrossRef

20.

Fajardo LF, Colby TV (1980) Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 104:584–588PubMed

21.

Kennedy AS, McNeillie P, Dezarn WA et al (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:1494–1500PubMedCrossRef

22.

Moroz P, Anderson JE, van Hazel GA, Gray BN (2001) Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78:248–252PubMedCrossRef

23.

Sharma RA, van Hazel GA, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25:1099–1106PubMedCrossRef

24.

Seidensticker R, Seidensticker M, Damm R et al (2012) Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: Sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 35:1109–1118PubMedCrossRef

25.

Ahmadzadehfar H, Meyer C, Ezziddin S et al (2013) Hepatic volume changes induced by radioembolization with (90)Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 40:80–90PubMedCrossRef

26.

Harandi A, Zaidi AS, Stocker AM, Laber DA (2009) Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009:567486PubMedCentralPubMedCrossRef

27.

Fernandez-Ros N, Silva N, Bilbao JI, et al. (2013) Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB (Oxford). doi:10.1111/hpb.12095

28.

Ayav A, Habib N, Jiao LR (2005) Portal hypertension secondary to 90-Yttrium microspheres: an unknown complication. J Clin Oncol 23:8275–8276PubMedCrossRef

29.

Stubbs RS (2006) Portal hypertension and liver surgery following selective internal radiation therapy with 90-Yttrium microspheres. J Clin Oncol 24:e15PubMedCrossRef

30.

Lau WY, Kennedy AS, Kim YH et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82:401–407PubMedCrossRef

31.

Rodrigues M, Sinzinger H (1994) Platelet labeling methodology and clinical applications. Thromb Res 76:399–432PubMedCrossRef

Title: Splenomegaly-Associated Thrombocytopenia After Hepatic Yttrium-90 Radioembolization
Authors: Marnix G. E. H. Lam
Arjun Banerjee
John D. Louie
Daniel Y. Sze
Publication date: 01-08-2014
Publisher: Springer US
Published in: CardioVascular and Interventional Radiology / Issue 4/2014
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-013-0742-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Splenomegaly-Associated Thrombocytopenia After Hepatic Yttrium-90 Radioembolization

Abstract

Purpose

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

A Prospective Randomized Trial of Catheter-Directed Thrombolysis With Additional Balloon Dilatation for Iliofemoral Deep Venous Thrombosis: A Single-Center Experience

Stereotactic Radiofrequency Ablation for Liver Tumors in Inherited Metabolic Disorders

Use of Percutaneous Aspiration Thrombectomy vs. Anticoagulation Therapy to Treat Acute Iliofemoral Venous Thrombosis: 1-year Follow-up Results of a Randomised, Clinical Trial

Safety and Efficacy of Target Vessel Catheterization with the New Steerable Microcatheter Direxion Compared with a Standard Microcatheter: A Prospective, Preclinical Trial

Efficacy of Magnetic Thermoablation Using SPIO in the Treatment of Osteoid Osteoma in a Bovine Model Compared to Radiofrequency and Microwave Ablation

Specialty Status for Interventional Radiology: The Time is Now